<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317925</url>
  </required_header>
  <id_info>
    <org_study_id>00046001</org_study_id>
    <nct_id>NCT03317925</nct_id>
  </id_info>
  <brief_title>Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)</brief_title>
  <acronym>RETASK</acronym>
  <official_title>Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In pediatric kidney transplant patients, rejection, medication toxicity and ischemia cause
      early and chronic renal allograft injury, which reduces graft lifespan and patient survival.
      Early detection of injury would facilitate prevention and treatment. The gold standard
      surveillance biopsy has limitations including delayed discovery of injury. No noninvasive
      test identifies graft injury before it is clinically apparent. This project's goal is to
      develop a novel early marker of subclinical graft injury to facilitate prompt recognition and
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney damage activates the traditional renin-angiotensin (Ang) system (RAS), characterized
      by Ang-converting enzyme (ACE)/Ang II/Ang II type 1 receptor. The Ang-converting enzyme 2
      (ACE2)/Ang-(1-7)/Mas pathway counteracts this damage. The balance, or ratio, between levels
      of the ACE/Ang II and ACE2/Ang-(1-7) pathways may be clinically important because Ang-(1-7)
      counteracts Ang II-mediated injury. An increase in ACE and Ang II expression and a decrease
      in ACE2 and Ang-(1-7) expression on tubular cells may promote renal injury. Tubular damage
      may increase urinary loss of protective ACE2 and Ang-(1-7), propagating renal damage by
      allowing ACE and Ang II to stimulate inflammation and fibrosis unopposed. The investigators
      hypothesis is that a shift in the urinary ACE-to-ACE2 and Ang II-to-Ang-(1-7) ratios towards
      ACE2 and Ang-(1-7) predicts acute graft injury diagnosed on renal biopsy and predicts chronic
      graft damage on renal biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2014</start_date>
  <completion_date type="Actual">April 26, 2017</completion_date>
  <primary_completion_date type="Actual">January 20, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute graft injury</measure>
    <time_frame>Within six months after kidney transplant</time_frame>
    <description>Renal biopsy-confirmed acute renal allograft injury as determined by a pathologist (binary yes or no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic graft damage</measure>
    <time_frame>Six months after kidney transplant</time_frame>
    <description>Renal biopsy-confirmed chronic renal allograft damage as determined by a quantitative fibrosis pathology stain (percent fibrosis from 0 to 100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Within six months after kidney transplant</time_frame>
    <description>Glomerular filtration rate by the Schwartz equation (mL/min/1.73 m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>Within six months after kidney transplant</time_frame>
    <description>Urine protein-to-creatinine ratio above 0.2 mg/mg creatinine</description>
  </secondary_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Renal Transplant</condition>
  <condition>Renin-Angiotensin System</condition>
  <condition>Rejection Acute Renal</condition>
  <condition>Rejection Chronic Renal</condition>
  <condition>Rejection of Renal Transplant</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Transplantation</intervention_name>
    <description>Kidney transplantation and biomarkers that can identify injury after transplant.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      De-identified urine and plasma specimens.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is an observational study with a convenience sample of patients recruited from Lucile
        Packard Children's Hospital kidney transplant evaluation clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 1 - 20 years

          -  Actively listed on the transplant list at Lucile Packard Children's Hospital at
             Stanford and received a renal transplant during the study enrollment period

        Exclusion Criteria:

          -  Transplanted at a center other than Lucile Packard Children's Hospital at Stanford
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M South, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Furness PN, Taub N, Assmann KJ, Banfi G, Cosyns JP, Dorman AM, Hill CM, Kapper SK, Waldherr R, Laurinavicius A, Marcussen N, Martins AP, Nogueira M, Regele H, Seron D, Carrera M, Sund S, Taskinen EI, Paavonen T, Tihomirova T, Rosenthal R. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol. 2003 Jun;27(6):805-10.</citation>
    <PMID>12766585</PMID>
  </reference>
  <reference>
    <citation>Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008 Apr;8(4):753-60. doi: 10.1111/j.1600-6143.2008.02159.x. Epub 2008 Feb 19.</citation>
    <PMID>18294345</PMID>
  </reference>
  <reference>
    <citation>Halawa A. The early diagnosis of acute renal graft dysfunction: a challenge we face. The role of novel biomarkers. Ann Transplant. 2011 Jan-Mar;16(1):90-8. Review.</citation>
    <PMID>21436782</PMID>
  </reference>
  <reference>
    <citation>Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol. 2010 Jan;21(1):189-97. doi: 10.1681/ASN.2009030264. Epub 2009 Sep 17.</citation>
    <PMID>19762491</PMID>
  </reference>
  <reference>
    <citation>Schaub S, Mayr M, Hönger G, Bestland J, Steiger J, Regeniter A, Mihatsch MJ, Wilkins JA, Rush D, Nickerson P. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation. 2007 Jul 15;84(1):104-12.</citation>
    <PMID>17627245</PMID>
  </reference>
  <reference>
    <citation>Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006 Nov;17(11):2985-91. Epub 2006 Oct 11. Review.</citation>
    <PMID>17035613</PMID>
  </reference>
  <reference>
    <citation>Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res. 2009 Jul;32(7):533-6. doi: 10.1038/hr.2009.74. Epub 2009 May 22. Review.</citation>
    <PMID>19461648</PMID>
  </reference>
  <reference>
    <citation>Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011 Jan;20(1):1-6. doi: 10.1097/MNH.0b013e3283406f57. Review.</citation>
    <PMID>21045683</PMID>
  </reference>
  <reference>
    <citation>Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs. 2005 Aug;14(8):1019-31. Review.</citation>
    <PMID>16050794</PMID>
  </reference>
  <reference>
    <citation>Santos RA, Ferreira AJ, Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008 May;93(5):519-27. doi: 10.1113/expphysiol.2008.042002. Epub 2008 Feb 29. Review.</citation>
    <PMID>18310257</PMID>
  </reference>
  <reference>
    <citation>Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. ScientificWorldJournal. 2009 Jun 30;9:522-35. doi: 10.1100/tsw.2009.70. Review.</citation>
    <PMID>19578709</PMID>
  </reference>
  <reference>
    <citation>Heringer-Walther S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, Gembardt F, Fichtner I, Schultheiss HP, Rodgers K, Walther T. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica. 2009 Jun;94(6):857-60. doi: 10.3324/haematol.2008.000034. Epub 2009 Apr 18.</citation>
    <PMID>19377080</PMID>
  </reference>
  <reference>
    <citation>Geara AS, Azzi J, Jurewicz M, Abdi R. The renin-angiotensin system: an old, newly discovered player in immunoregulation. Transplant Rev (Orlando). 2009 Jul;23(3):151-8. doi: 10.1016/j.trre.2009.04.002. Review.</citation>
    <PMID>19539879</PMID>
  </reference>
  <reference>
    <citation>Miyake-Ogawa C, Miyazaki M, Abe K, Harada T, Ozono Y, Sakai H, Koji T, Kohno S. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol. 2005 Jan-Feb;25(1):1-12. Epub 2005 Jan 7.</citation>
    <PMID>15644622</PMID>
  </reference>
  <reference>
    <citation>Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol. 2007 Apr;18(4):1093-102. Epub 2007 Feb 28.</citation>
    <PMID>17329576</PMID>
  </reference>
  <reference>
    <citation>Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 2006 Jun;69(12):2212-8. Epub 2006 May 3.</citation>
    <PMID>16672906</PMID>
  </reference>
  <reference>
    <citation>Moon JY. ACE2 and Angiotensin-(1-7) in Hypertensive Renal Disease. Electrolyte Blood Press. 2011 Dec;9(2):41-4. doi: 10.5049/EBP.2011.9.2.41. Epub 2011 Dec 31.</citation>
    <PMID>22438854</PMID>
  </reference>
  <reference>
    <citation>Ahmed AK, El Nahas AM, Johnson TS. Changes in matrix metalloproteinases and their inhibitors in kidney transplant recipients. Exp Clin Transplant. 2012 Aug;10(4):332-43.</citation>
    <PMID>22845765</PMID>
  </reference>
  <reference>
    <citation>Castoldi G, di Gioia CR, Travaglini C, Busca G, Redaelli S, Bombardi C, Stella A. Angiotensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: evidence of a pressure-independent effect. Clin Exp Pharmacol Physiol. 2007 Mar;34(3):205-9.</citation>
    <PMID>17250640</PMID>
  </reference>
  <reference>
    <citation>Mazanowska O, Kamińska D, Krajewska M, Zabińska M, Kopeć W, Boratyńska M, Chudoba P, Patrzalek D, Klinger M. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury. Transplant Proc. 2011 Oct;43(8):3000-3. doi: 10.1016/j.transproceed.2011.08.012.</citation>
    <PMID>21996210</PMID>
  </reference>
  <reference>
    <citation>Ling XB, Sigdel TK, Lau K, Ying L, Lau I, Schilling J, Sarwal MM. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol. 2010 Apr;21(4):646-53. doi: 10.1681/ASN.2009080876. Epub 2010 Feb 11.</citation>
    <PMID>20150539</PMID>
  </reference>
  <reference>
    <citation>Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation. 2005 Mar 27;79(6):655-61.</citation>
    <PMID>15785371</PMID>
  </reference>
  <reference>
    <citation>Pan CH, Wen CH, Lin CS. Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol. 2008 May;93(5):599-612. doi: 10.1113/expphysiol.2007.041830. Epub 2008 Feb 22.</citation>
    <PMID>18296491</PMID>
  </reference>
  <reference>
    <citation>Clark MA, Tallant EA, Diz DI. Downregulation of the AT1A receptor by pharmacologic concentrations of Angiotensin-(1-7). J Cardiovasc Pharmacol. 2001 Apr;37(4):437-48.</citation>
    <PMID>11300657</PMID>
  </reference>
  <reference>
    <citation>Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Sarao R, Penninger J, Ferrario CM. Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension. 2003 Oct;42(4):749-53. Epub 2003 Jul 21.</citation>
    <PMID>12874086</PMID>
  </reference>
  <reference>
    <citation>Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol. 2008 May;172(5):1174-83. doi: 10.2353/ajpath.2008.070762. Epub 2008 Apr 10.</citation>
    <PMID>18403595</PMID>
  </reference>
  <reference>
    <citation>Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, Yao X, Chen ZY, Vanhoutte PM, Huang Y. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J. 2012 Dec;33(23):2980-90. doi: 10.1093/eurheartj/ehr459. Epub 2012 Jan 19.</citation>
    <PMID>22267242</PMID>
  </reference>
  <reference>
    <citation>Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, Quarles LD. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012;7(9):e44161. doi: 10.1371/journal.pone.0044161. Epub 2012 Sep 6.</citation>
    <PMID>22970174</PMID>
  </reference>
  <reference>
    <citation>Ejaz AA, Kambhampati G, Ejaz NI, Dass B, Lapsia V, Arif AA, Asmar A, Shimada M, Alsabbagh MM, Aiyer R, Johnson RJ. Post-operative serum uric acid and acute kidney injury. J Nephrol. 2012 Jul-Aug;25(4):497-505. doi: 10.5301/jn.5000173.</citation>
    <PMID>22684655</PMID>
  </reference>
  <reference>
    <citation>el-Agroudy AE, Hassan NA, Foda MA, Ismail AM, el-Sawy EA, Mousa O, Ghoneim MA. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol. 2003 Sep-Oct;23(5):300-6. Epub 2003 Aug 6.</citation>
    <PMID>12904684</PMID>
  </reference>
  <reference>
    <citation>Haririan A, Metireddy M, Cangro C, Nogueira JM, Rasetto F, Cooper M, Klassen DK, Weir MR. Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis. Am J Transplant. 2011 Sep;11(9):1943-50. doi: 10.1111/j.1600-6143.2011.03613.x. Epub 2011 Aug 3.</citation>
    <PMID>21812917</PMID>
  </reference>
  <reference>
    <citation>Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003 Jun;41(6):1287-93. Epub 2003 May 12.</citation>
    <PMID>12743010</PMID>
  </reference>
  <reference>
    <citation>Numakura K, Satoh S, Tsuchiya N, Saito M, Maita S, Obara T, Tsuruta H, Inoue T, Narita S, Horikawa Y, Kagaya H, Miura M, Habuchi T. Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. Transplantation. 2012 Jul 27;94(2):145-51. doi: 10.1097/TP.0b013e318254391b.</citation>
    <PMID>22728291</PMID>
  </reference>
  <reference>
    <citation>Feig DI. Hyperuricemia and hypertension. Adv Chronic Kidney Dis. 2012 Nov;19(6):377-85. doi: 10.1053/j.ackd.2012.05.009.</citation>
    <PMID>23089272</PMID>
  </reference>
  <reference>
    <citation>Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Philipp T, Heemann U. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int. 2000 Mar;57(3):982-91.</citation>
    <PMID>10720951</PMID>
  </reference>
  <reference>
    <citation>Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant. 2007 Jan;7(1):243-8.</citation>
    <PMID>17227571</PMID>
  </reference>
  <reference>
    <citation>Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996 Jun;14(6):799-805.</citation>
    <PMID>8793704</PMID>
  </reference>
  <reference>
    <citation>Shah PR, Kute VB, Saboo DS, Goplani KR, Gumber MR, Vanikar AV, Patel HV, Trivedi HL. Safety and efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic allograft injury. Saudi J Kidney Dis Transpl. 2011 Nov;22(6):1128-32.</citation>
    <PMID>22089769</PMID>
  </reference>
  <reference>
    <citation>Arbeiter K, Pichler A, Stemberger R, Mueller T, Ruffingshofer D, Vargha R, Balzar E, Aufricht C. ACE inhibition in the treatment of children after renal transplantation. Pediatr Nephrol. 2004 Feb;19(2):222-6. Epub 2003 Dec 13.</citation>
    <PMID>14673630</PMID>
  </reference>
  <reference>
    <citation>Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM, Scholey JW. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol. 2006 Jun;168(6):1808-20.</citation>
    <PMID>16723697</PMID>
  </reference>
  <reference>
    <citation>Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, Sakai K, Ishikawa Y, Shibuya K, Hase H, Aikawa A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008 Apr;51(4):613-23. doi: 10.1053/j.ajkd.2007.11.022. Epub 2008 Mar 4.</citation>
    <PMID>18371537</PMID>
  </reference>
  <reference>
    <citation>Mizuiri S, Hemmi H, Arita M, Aoki T, Ohashi Y, Miyagi M, Sakai K, Shibuya K, Hase H, Aikawa A. Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy. Nephron Clin Pract. 2011;117(1):c57-66. doi: 10.1159/000319648. Epub 2010 Aug 4.</citation>
    <PMID>20689326</PMID>
  </reference>
  <reference>
    <citation>Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, Aikawa A. Urinary angiotensin-converting enzyme 2 in patients with CKD. Nephrology (Carlton). 2011 Aug;16(6):567-72. doi: 10.1111/j.1440-1797.2011.01467.x.</citation>
    <PMID>21457402</PMID>
  </reference>
  <reference>
    <citation>Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, Fergusson D, Kennedy CR, Burns KD. Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLoS One. 2012;7(5):e37649. doi: 10.1371/journal.pone.0037649. Epub 2012 May 22.</citation>
    <PMID>22629438</PMID>
  </reference>
  <reference>
    <citation>Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol. 2003 Jun;14(6):1662-8.</citation>
    <PMID>12761269</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric Renal Transplant</keyword>
  <keyword>Renal Allograft</keyword>
  <keyword>Angiotensin II</keyword>
  <keyword>Angiotensin-(1-7)</keyword>
  <keyword>ACE</keyword>
  <keyword>ACE2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

